Key Points
- Insider purchase: Director Kate Mitchell bought 2,350 shares at an average price of $42.48 (about $99,828), increasing her stake by 38.77% to 8,411 shares (valued ~ $357,299).
- Material impairment and weaker outlook: Ralliant disclosed a roughly $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment and reduced FY2026 guidance, a significant hit to fundamentals.
- Market and legal fallout: Short interest surged (~+58.7% to ~3.75M shares), multiple law firms opened investigations into the impairment/disclosure, and several analysts have cut price targets while consensus remains a "Hold" (target ~$50.50).
Ralliant Corporation (NYSE:RAL - Get Free Report) Director Kate Mitchell purchased 2,350 shares of the company's stock in a transaction on Tuesday, February 10th. The shares were bought at an average price of $42.48 per share, with a total value of $99,828.00. Following the completion of the transaction, the director owned 8,411 shares of the company's stock, valued at approximately $357,299.28. The trade was a 38.77% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
Ralliant Price Performance
Ralliant stock opened at $42.68 on Friday. The company's 50 day simple moving average is $50.93 and its 200-day simple moving average is $46.59. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $57.02. The company has a market capitalization of $4.81 billion and a price-to-earnings ratio of 21.78.
Ralliant (NYSE:RAL - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. The company's revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.
Ralliant Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Monday, March 9th. Ralliant's payout ratio is currently 10.20%.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on RAL shares. Truist Financial dropped their target price on Ralliant from $62.00 to $49.00 and set a "buy" rating for the company in a research report on Friday, February 6th. Vertical Research raised shares of Ralliant from a "hold" rating to a "buy" rating and set a $45.00 target price on the stock in a research note on Friday, February 6th. Oppenheimer reduced their target price on shares of Ralliant from $60.00 to $50.00 and set an "outperform" rating on the stock in a report on Friday, February 6th. Citigroup dropped their price target on shares of Ralliant from $61.00 to $51.00 and set a "buy" rating for the company in a research note on Friday, February 6th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $45.00 price objective on shares of Ralliant in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $50.50.
Get Our Latest Stock Report on Ralliant
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in RAL. Dodge & Cox acquired a new stake in shares of Ralliant in the 2nd quarter valued at $523,571,000. Viking Global Investors LP purchased a new position in Ralliant in the second quarter valued at $257,200,000. State Street Corp purchased a new position in Ralliant in the second quarter valued at $213,096,000. Flossbach Von Storch SE acquired a new stake in Ralliant in the second quarter valued at $198,077,000. Finally, Norges Bank purchased a new stake in Ralliant during the 4th quarter worth about $124,687,000.
Trending Headlines about Ralliant
Here are the key news stories impacting Ralliant this week:
- Positive Sentiment: Company insiders have been buying shares, signaling management confidence — Director Kate Mitchell purchased 2,350 shares at ~$42.48 and Director Anelise Angelino Sacks bought 2,000 shares (disclosed in SEC filings). These purchases can support the stock and signal perceived undervaluation. Kate Mitchell SEC Filing Anelise Angelino Sacks SEC Filing
- Neutral Sentiment: Management will present at upcoming investor conferences (Citi and Barclays on Feb 17–18), offering a platform to clarify strategy and guidance — useful for investors seeking more detail but not an immediate catalyst. Conference Announcement
- Neutral Sentiment: Several sell‑side firms trimmed price targets (Barclays, Citigroup, Truist, Oppenheimer) — these lower targets reduce near‑term enthusiasm but many analysts retained positive ratings, leaving mixed guidance for investors. Barclays / Analyst Notes
- Negative Sentiment: Ralliant disclosed a roughly $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment and reduced FY2026 guidance — a material accounting charge and weaker outlook that hit fundamentals and triggered large analyst re‑ratings. Impairment / Guidance Report
- Negative Sentiment: Multiple law firms (Levi & Korsinsky, Kessler Topaz, Block & Leviton, Kaplan Fox and others) have opened or publicized investigations into possible securities‑law violations related to the impairment timing/disclosure — raising litigation, regulatory and reputational risk. Kessler Topaz PR Block & Leviton Alert
- Negative Sentiment: Short interest rose sharply (~+58.7% in January to ~3.75M shares), amplifying downside pressure and intraday volatility as bearish positioning increases the risk of further selling on negative headlines.
- Negative Sentiment: Zacks downgraded Ralliant to a "strong sell," adding to negative analyst momentum and likely contributing to selling pressure. Zacks Note
About Ralliant
(
Get Free Report)
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
